This website is intended for professionals in medicine and healthcare. By selecting “Confirm”, I declare that I am a member of this professional audience. I also agree to the publisher’s rules for using its information resource. Publisher’s resource rules (Russian)
Molecular Medicine
Found: 20
Aim of the study. The possibility of using antitumor drugs against the background of active tuberculosis is an unresolved problem of modern medicine. The aim of the experimental study was to study the course of tuberculosis infection against the background of …
Introduction. Up to 20% of tuberculosis patients suffer from malignant neoplasms. In this case, the combination of both diseases in the lung is a particular problem. More than 60% of patients cannot complete combination therapy due to drug-resistant MBT. The a…
Introduction. Lung cancer occupies a leading position in the structure of mortality from cancer. Chronic inflammation characteristic of tuberculosis increases the risk of lung cancer. Currently, more and more information is emerging confirming the cause-and-ef…
Introduction. Treatment of the coexistent pathology of lung cancer and tuberculosis remains the prerogative of experimental research, since the optimal treatment strategy for the coexistence of these two diseases has not yet been developed. The purpose was to …
Introduction. Lung carcinoma is one of the most common cancers and the most likely cause of cancer mortality in the world. The use of the IHC method to determine the immunophenotype of tumor cells greatly facilitates the differential diagnostic search, allows …
This review is devoted to summarizing the available data on the expression of long non-coding RNAs (lncRNAs) in lung cancer cells and tissues, their role in tumorigenesis, association with clinical and morphological characteristics and disease prognosis. The p…
Introduction. Lung cancer and tuberculosis, make a significant affect to the morbidity and mortality of the population in Russia and in the world. Strategy of medication therapy has not been developed for cases when these diseases are combined. The aim of the …
Introduction. One of the problems of modern medicine is the low efficiency of treatment of patients with a coexistence of lung cancer and active tuberculosis. Optimal treatment regimens for coexistence pathology have not been developed at present. In recent ye…
Introduction. Small cell lung cancer (SCLS) is a highly aggressive type of tumor, and various compounds are considered as potential biochemical markers of its prognosis, including neuron-specific enolase (NSE), chromogranin A (CgA), and prograstrin releasing p…
The pathology of the respiratory organs is the leading one in the structure of the general human morbidity. Every year the number of diseases of the respiratory system increases, and the associated mortality increases in parallel. The study of the causes and m…
Lung cancer occupies the leading position in at the structure of oncological morbidity in the developed countries. The overall five-year survival rate for lung cancer isn’t exceed to 10–20% even using of the entire modern arsenal of therapeutic methods. Multip…
Background. Lung cancer is the most frequent cause of cancer mortality. The prevailing type is non-small cell lung cancer (NSCLC), in the treatment of which EGFR tyrosine kinase inhibitors are actively used, as well as a combination of BRAF and MEK inhibitors.…
The review is devoted to the studies of immune check-point (programmed death) molecules – PD-1 receptor and its ligands PD-L1 and PD-L2, which play an important role in the regulation of immune response. Special attention is paid to soluble (s) forms of PD-1 a…
Background. Genotyping of the tumor samples is necessary for a personalized approach in the treatment of patients with malignancies. The identification of somatic mutations in EGFR and KRAS genes can help to predict the course of the disease and to individuali…
Introduction. Despite the continuous improvement of the surgical method of treatment of patients with non-small cell lung cancer (NSCLC), there is no noticeable tendency to improve survival data. This 5-year index does not exceed 15–25%. In this regard, it is …
Surgery results of the treatment of the stage II–III lung cancer remains to be unsatisfactory, and used the chemotherapy fails to improve the survival. The main obstacle is the use of standard clinical parameters for the treatment strategy and not enough effec…
Introduction. EGFR mutation and EML4-ALK fusion are the most clinically significant genetic alterations in non-small cell lung cancer. Numerous studies have been devoted to EGFR mutations and their association with phenotypic clinical and pathological characte…
The most important event in the molecular biology of the last years is the discovery of the regulation of intracellular processes by micro RNAs – a product of complicated processing of precursor RNAs synthesized on nuclear genes, that are playing the key role …
Lung cancer is one of the most common oncologic diseases in the world and the most frequent cause of the death from malignant neoplasms. Last decade’s studies revealed significant number of molecular events leading to the onset and development of non-small cel…
Last successful results in target therapy of cancer were achieved with different tyrosine kinases inhibitors (TKI). Target therapy of non-small cell lung cancer (NSCLC) with EGFR inhibitors gefitinib and erlotinib is effective only in patients with somatic mut…